When combating a multi-drug resistant pathogen, sometimes it is better to target the mechanism of the resistance rather than to develop new antibiotics. Efflux pumps remove the antibiotic from the cell before it can be effective. But a combination therapy with an efflux pump inhibitor keeping the antibiotic active and inside the cell could be an excellent treatment. In this paper by Lowrence et al. screened a series of dithiazole thione derivatives for their efflux inhibitor ability. In addition to in vitro testing, they used the zebrafish in the in vivo model of soft-tissue infection by Methicillin-resistant S. aureus (MRSA).

Read more here: http://link.springer.com/article/10.1007%2Fs00253-016-7759-2